AI Platforms · Platform Profile
Supio is an agentic AI platform for plaintiff personal injury and mass tort firms — branded CaseAware AI — distributed in partnership with Thomson Reuters and integrated with Westlaw.
Supio was founded in 2021 in Seattle by childhood friends Jerry Zhou and Kyle Lam. The platform ingests and structures case documents — medical records, bills, transcripts — for plaintiff firms and applies AI agents to produce work product across the life of a case: medical chronologies, demand letters, litigation drafts, and deposition analysis, plus firm-level analytics across the caseload.
Its platform is branded CaseAware AI, and a distinctive strategic asset is its relationship with Thomson Reuters: TR Ventures is an investor, Thomson Reuters distributes CaseAware AI to its customers under a September 2025 partnership, and in April 2026 Supio launched a direct case-intelligence integration with Westlaw Advantage. In 2025 it expanded into intake and litigation agent suites, positioning agents at both the case level and the firm level.
The company raised a $60 million Series B in April 2025 led by Sapphire Ventures, bringing total funding to $91 million, and reported that annual recurring revenue quadrupled between the Series A and Series B. It reported more than 27,000 cases processed and support of over $1 billion in settlements in the year before the round. Unlike some competitors in the category, no published accuracy controversies were found in reputable press as of July 2026.
Plaintiff-side personal injury and mass tort firms, small to large — not general litigation. The explicit mass tort product line distinguishes it from single-event PI tools, and the Westlaw integration matters most to firms already inside the Thomson Reuters ecosystem.
| Vendor | Supio Inc. — independent, venture-backed |
|---|---|
| Founded / HQ | 2021; Seattle, WA |
| Founders | Jerry Zhou (CEO), Kyle Lam |
| Category | Agentic AI platform for PI and mass tort (CaseAware AI) |
| Scale | 27,000+ cases processed; $1B+ in supported settlements (company figures, 2025) |
| Funding | $91M total; $60M Series B led by Sapphire Ventures, April 2025 (Thomson Reuters Ventures participating) |
| Pricing model | Quote-based; 'risk-free pricing model' announced 2025, details unpublished |
| Key integrations | Litify, MyCase, CasePeer; Westlaw / Westlaw Advantage (April 2026) |
| Compliance | SOC 2 Type II, HIPAA, PHIPA, GDPR (stated) |
| Website | supio.com |
Supio competes head-on with EvenUp for the AI layer above a PI firm's case management system, and the practical differences show up in distribution and integration: Supio's Thomson Reuters partnership routes it through Westlaw's install base, while its CMS integration list (Litify, MyCase, CasePeer) is shorter than EvenUp's — firms on Filevine or SmartAdvocate should confirm current coverage.
Its agentic framing — agents operating at the case level and the firm level — points at where this category is heading: not one document type automated, but a layer that watches the whole caseload. Evaluations should test that claim against the firm's actual matter mix, especially in mass tort dockets where volume magnifies both value and error.
Both — mass tort handling is an explicit product line alongside single-plaintiff personal injury work.
SOC 2 Type II, HIPAA, PHIPA, and GDPR compliance are stated on its site.
It lists Litify, MyCase, and CasePeer among integrations. Firms on other systems should confirm current coverage directly.
Thomson Reuters Ventures is an investor, TR distributes CaseAware AI to its customers under a September 2025 partnership, and a Westlaw Advantage integration was added in April 2026.
Systems firms typically evaluate alongside Supio — competitors, complements, and the adjacent layers of the same stack.
Evaluating Supio — or trying to get more out of it? Send the question. A real person answers.
This page is an independent editorial overview published by Maestro Strategic Partners, an operations and AI consultancy for plaintiff law firms. Maestro is not affiliated with, sponsored by, or endorsed by Supio Inc. Supio and related marks are the property of their respective owners; they are used here for identification only. Product details verified as of July 2026 and may have changed — confirm specifics with the vendor.
